Scarica l'app Stockscreener
2.73
1.49%
0.04
Precedente Chiudi:
$2.69
Aprire:
$2.7
Volume 24 ore:
14,840
Relative Volume:
0.18
Capitalizzazione di mercato:
$69.34M
Reddito:
$130.00K
Utile/perdita netta:
$-21.29M
Rapporto P/E:
-1.3809
EPS:
-1.977
Flusso di cassa netto:
$-18.29M
1 W Prestazione:
+10.98%
1M Prestazione:
+27.57%
6M Prestazione:
+63.47%
1 anno Prestazione:
-48.30%
Intervallo 1D:
$2.5121
$2.74
Intervallo di 1 settimana:
$2.38
$2.74
Portata 52W:
$1.22
$5.83
Serina Therapeutics Inc Stock (SER) Company Profile
Nome
Serina Therapeutics Inc
Settore
Industria
Telefono
(256) 327-9630
Indirizzo
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.73 | 67.31M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Iniziato | H.C. Wainwright | Buy |
Serina Therapeutics Inc Borsa (SER) Ultime notizie
BTIG Maintains Serina Therapeutics(SER.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Serina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero - scanx.trade
Serina Therapeutics Completes Dosing for 8 Parkinson’s Patients - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SER Q1 2026 Earnings: Wider Loss Falls Short of Estimates Despite Modest Share GainEarnings Trend Analysis - vinanet.vn
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics (SER) Holds Steady Above $2.24 Support, Up 0.43% in Measured SessionVolatility Smile - dars.gov.et
Serina Therapeutics (SER) Advances 5.83% to $2.18, Approaching Key Resistance at $2.29Wave Truncation - vinanet.vn
SER Q1 2026 Earnings: Wider-than-Expected Loss of -$0.58 per Share Signals Rising Pipeline CostsEarnings Call Highlights - Vinanet
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Serina Therapeutics (SER) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseEstimate Dispersion - dars.gov.et
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewswire
Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Nigeria
Juvenescence group reports 27.3% Serina Therapeutics (SER) beneficial stake - Stock Titan
Serina Therapeutics (SER) Gains Ground: Testing Resistance at $2.28VWAP Breakout - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises 7.58%Financial Data - dars.gov.et
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Miss Exceeds 30% as Clinical-Stage Firm Ramps R&D SpendEPS Growth Report - Vinanet
SER Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Pipeline AdvancesEarnings Growth Forecast - po-news-eg.net
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Call Transcript - vinanet.vn
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Taiwan News
Serina Therapeutics director Brannan buys $2,029 in stock - Investing.com UK
Insider Buying: Stephen Brannan Acquires Shares of Serina Therap - GuruFocus
Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
Serina Therapeutics Inc Azioni (SER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Serina Therapeutics Inc Azioni (SER) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venkatesan Jay | Director |
May 22 '26 |
Buy |
1.78 |
589 |
1,048 |
589 |
| WILSON KAREN J | Director |
Jun 11 '26 |
Buy |
1.75 |
5,100 |
8,900 |
5,100 |
| WILSON KAREN J | Director |
Jun 12 '26 |
Buy |
1.77 |
5,000 |
8,850 |
10,100 |
| WILSON KAREN J | Director |
May 22 '26 |
Buy |
1.93 |
10,000 |
19,300 |
20,000 |
| WILSON KAREN J | Director |
May 21 '26 |
Buy |
1.77 |
10,000 |
17,700 |
10,000 |
| Marshall Richard Peter | Director |
May 19 '26 |
Buy |
1.65 |
12,183 |
20,102 |
12,183 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Option Exercise |
0.06 |
6,500 |
390 |
6,500 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Sale |
2.86 |
6,500 |
18,568 |
0 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Option Exercise |
0.06 |
39,000 |
2,340 |
39,000 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Sale |
2.50 |
39,000 |
97,500 |
0 |
0.86%
0.31%
Capitalizzazione:
|
Volume (24 ore):